Ending Gender Inequality in Cardiovascular Clinical Trial Leadership: JACC Review Topic of the Week
Van Spall HGC., Lala A., Deering TF., Casadei B., Zannad F., Kaul P., Mehran R., Pearson GD., Shah MR., Gulati M., Grines C., Volgman AS., Revkin JH., Piña I., Lam CSP., Hochman JS., Simon T., Walsh MN., Bozkurt B.
Women are under-represented as leaders of cardiovascular randomized controlled trials, representing 1 in 10 lead authors of cardiovascular trials published in high-impact journals. Although the proportion of cardiovascular specialists who are women has increased in recent years, the proportion of cardiovascular clinical trialists who are women has not. This gap, underpinned by systemic sexism, has not been adequately addressed. The benefits of diverse randomized controlled trial leadership extend to patients and professionals. In this position statement, we present strategies adopted by some organizations to end gender inequality in research leadership. We offer an actionable roadmap for early-career researchers, scientists, academic institutions, professional societies, trial sponsors, and journals to follow, with the goal of harnessing the strength of women and under-represented groups as research leaders and facilitating a just culture in the cardiovascular clinical trial enterprise.